Monte Rosa Therapeutics Overview

Monte Rosa Therapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for GLUE.

Quarterly EBIT

-$50.03M

↓ 213.62% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$150.40M

↓ 6964.49% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin